


# ORGANIC SEMINAR

## Dr. Frank Kotch


World Wide Research & Development  
Pfizer Inc.




Conjugation




Analytics



Purification



Process



Friday, November 9th  
9:00 am

473 Hutchison Hall

University of Rochester  
Department of Chemistry

## Title: "Antibody Drug Conjugates: Process Development of Complex Biologic Medicines"

**Abstract:** Antibody drug conjugates (ADCs) are a class of biopharmaceutical drugs that are composed of an antibody that is chemically linked to one or more cytotoxic small molecules. These conjugates are designed as anti-cancer agents that combine the unique selectivity of antibodies as targeted therapy with very potent small molecule compounds that inhibit or kill cancer cells. Pfizer employs several conjugation chemistries via cysteine, lysine or glutamine residues on the antibody as well as several different linkers and payloads to construct ADCs. Each ADC molecule, even those built using the same conjugation chemistry, poses unique challenges for process and analytical development. Process development of ADCs and their associated challenges will be presented.

Host: Professor Bradley Nilsson • Email: [nilsson@chem.rochester.edu](mailto:nilsson@chem.rochester.edu)

